Loading stock data…
NewAmsterdam Pharma Company N.V (NAMS)
$25.63+0.23 (+0.91%)
Market ClosedLast close Sep 8
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
NewAmsterdam Pharma Company N.V. in the Healthcare sector is trading at $25.63 with a market capitalization of $2.9B. Wall Street consensus targets $51.68 (15 analysts), implying a +101.6% move over the next 12 months. The stock is currently near its 52-week low of $23.05, remaining 21.1% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +101.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $3.04M↑ | $32,000↓ | $348,000↓ | $19.14M↑ | $2.98M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$58.42M↑ | -$65.98M↓ | -$55.14M↓ | -$35.63M↑ | -$68.92M |
| Net Income | -$48.44M↑ | -$74.92M↓ | -$72.00M↓ | -$17.36M↑ | -$39.53M |
Peer Comparison
JNJUNHPFE
Fundamentals
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP)...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.91B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.11
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-41.10%
Volume
Today's trading volume
3.80M
Recent News
How Novartis' Double-Stacked Failures Reverberated Through Biopharma
Novartis and Ionis' high-profile Lp(a) flop on Friday reverberated through biotech stocks on Tuesday, leading to a widespread drop.
Novartis Trial Failure Sparks Biopharma Options Frenzy
3 biopharma stocks seeing high options volume
NewAmsterdam Pharma Maps Obicetrapib Strategy as PREVAIL Interim Nears
NewAmsterdam Pharma (NASDAQ:NAMS) used its annual Investor Day to outline its cardiovascular outcomes strategy for obicetrapib, provide updates on additional clinical programs and discuss commercial preparations ahead of a potential European launch. Chief Executive Officer Michael Davidson said the
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Lags Revenue Estimates
NewAmsterdam Pharma Company N.V. (NAMS) delivered earnings and revenue surprises of -8.33% and -45.41%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
A Look At NewAmsterdam Pharma (NAMS) Valuation After Recent Share Price Weakness
Recent trading context for NewAmsterdam Pharma (NasdaqGM:NAMS) NewAmsterdam Pharma (NasdaqGM:NAMS) has drawn fresh attention after recent trading, with the stock closing at US$29.33. The move comes alongside a month-long decline of about 26% and a year-to-date drop near 17%. See our latest analysis for NewAmsterdam Pharma. The recent 1 month share price return, down 25.92%, suggests momentum has cooled in the short term, even as the 1 year total shareholder return of 43.07% and very large 3...